Mobile

A multicenter open label study to compare efficacy and safety of induction treatment by ATG (thymoglobulin) versus anti-IL-2R (daclizumab) with a triple drug regimen (tacrolimus, mycophenolate mofetil...

Mise à jour : Il y a 5 ans
Référence :

A multicenter open label study to compare efficacy and safety of induction treatment by ATG (thymoglobulin) versus anti-IL-2R (daclizumab) with a triple drug regimen (tacrolimus, mycophenolate mofetil, prednisone) in high risk renal transplant recipients

  • | Pays :
  • France
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

Critère d'inclusion

  • Incidence of acute rejection in renal transplantation

Liens